Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) infusion is associated with early toxicity. Yet, whether early toxicity development holds ramifications for long-term outcomes is unknown. METHODS: From a large cohort of consecutive adult patients treated with CAR-T therapies for relapsed or refr...

Full description

Bibliographic Details
Main Authors: Brammer, Jonathan E, Braunstein, Zachary, Katapadi, Aashish, Porter, Kyle, Biersmith, Michael, Guha, Avirup, Vasu, Sumithira, Yildiz, Vedat O, Smith, Sakima A, Buck, Benjamin, Haddad, Devin, Gumina, Richard, William, Basem M, Penza, Sam, Saad, Ayman, Denlinger, Nathan, Vallakati, Ajay, Baliga, Ragavendra, Benza, Raymond, Binkley, Philip, Wei, Lai, Mocarski, Mason, Devine, Steven M, Jaglowski, Samantha, Addison, Daniel
Format: Online Article Text
Language:English
Published: BMJ Publishing Group 2021
Subjects:
Immunotherapy Biomarkers
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386216/
https://www.ncbi.nlm.nih.gov/pubmed/34429331
http://dx.doi.org/10.1136/jitc-2020-002303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386216/
https://www.ncbi.nlm.nih.gov/pubmed/34429331
http://dx.doi.org/10.1136/jitc-2020-002303

Similar Items